Provenance Record

Clear, well-structured News piece. Overview leads with the headline result, What We Know presents primary and secondary endpoints and safety data with explicit per-source attribution, and What We Don't Know appropriately frames the limitations.

All three source snapshots read from disk and verified. source-0.html.gz (GlobeNewswire press release, 200): confirms the headline numbers cited to it — 220 vs 129 catheter-free days, 91-day advantage, p=0.00070, infection rate 6 vs 23 per 100 patient-years, no spontaneous ruptures, supplemental BLA planned H2 2026, December 2024 FDA BLA approval in the vascular injury indication, and the June 11 2026 SVS VAM presentation in the Women's Health seminar with a June 10 2026 dateline. source-1.html.gz (BioSpace, 200): confirms the 120-of-150 enrollment, the end-stage kidney disease / AV fistula maturation failure population, the absolute infection figures (zero ATEV vs three AVF), no spontaneous ruptures, and the Shamik Parikh verbatim quote. source-2.html.gz (StockTitan 8-K summary, 200): confirms the first-80-patient interim split (ATEV N=40, AVF N=40) and every secondary-endpoint specific cited to it — Six-Month Catheter-Free Days 88.4 vs 32.3 (p=0.00009), 12-Month Functional Patency 250.1 vs 151.7 (p=0.00057), Six-Month Secondary Patency 87.5% vs 65.0% (p=0.0013), and 12-Month Secondary Patency 77.5% vs 62.5% (p=0.16, not significant).

Every number, name, code, and date traces to a cited source and matches the snapshot exactly. Rule 9 attribution satisfied: V012 headline numbers cited to the Humacyte/GlobeNewswire release; secondary-endpoint specifics cited to the StockTitan 8-K filing summary. The Parikh quote ('Patients receiving an ATEV had an average of three months additional catheter-free time as compared to AV fistula, a highly significant outcome') is verbatim in BioSpace. The June 11 2026 presentation date and June 10 2026 release dateline are confirmed in both the press release and BioSpace; no June 15 date appears in any cited source, so there is no conflict to resolve. The article correctly identifies the one non-significant secondary endpoint (12-month secondary patency, p=0.16). The non-cited SEC EDGAR page (which returns 403) is correctly NOT among the article's sources.

High-quality, accurately sourced News submission. Interim-analysis nature is consistently and appropriately framed as top-line interim results rather than final/peer-reviewed data. APPROVE.